In the early 1940s, Pfizer executive John Smith wrote of the revolutionary drug penicillin: “[T]he yields are low, the isolation is difficult, the extraction is murder, the purification invites disaster, and the assay is unsatisfactory.”1
He was referring to the challenges that Pfizer, along with teams at Merck, Squibb, Eli Lilly and other companies tasked with engineering penicillin, faced in producing the antibiotic on a global scale. Fortunately, manufacturing techniques eventually caught up to the pace of medical innovation, and penicillin went on to save countless lives worldwide.
From antibiotics to biologics, every transformative new drug class has faced this challenge. Manufacturing limitations at first preclude large-scale production. That, in turn, makes it challenging to treat large patient populations.
At Generation Bio, our goal is to bring the life-altering benefits of gene therapy to more people, living with a broader range of diseases, in more places around the world.
Today, the same can be said of gene therapy. The extensive capabilities required for viral manufacturing are costly. The limited scalability of the process makes the drug substance expensive and unable to address larger indications where the quantity of vector cannot increase with the size of the patient population. The processes involved in purification, logistics and distribution drive up costs even further. In practice, that has meant that these transformative treatments are available only to small therapeutic indications and to patients in wealthier nations, such as the U.S. and Europe.
At Generation Bio, our goal is to bring the life-altering benefits of gene therapy to more people, living with a broader range of diseases, in more places around the world. To do this, we’re pioneering a new, non-viral approach to delivery with the potential to unlock substantial scope and scale.
Our linear, closed-ended DNA technology, or ceDNA, is able to deliver a healthy transgene into the nucleus of a patient’s cells without using a viral capsid. Without the need for a capsid, we can deliver vectors that are larger than can fit into AAV and therefore open up a broader set of indications. Additionally, the process of manufacturing ceDNA is comparable to a traditional biologic, rather than a virus like AAV. As a result, it is far less costly and scalable at high purity to larger patient populations.
This represents a potential breakthrough approach for a multitude of diseases. One critical example is hemophilia, a rare, genetic blood disease of the liver. AAV-based gene therapies have demonstrated therapeutic potential for hemophilia, but because of manufacturing and cost constraints are not easily scalable to broad populations, significantly limiting their societal impact.
Because we’re able to use standard biologics infrastructure, our novel vector and LNP delivery approach enables development and manufacturing of gene therapies at a higher capacity and consequently a dramatically lower cost relative to AAV. This approach has the potential to greatly expand the reach of gene therapy to larger disease areas, and to make therapies accessible to populations outside of the U.S. and E.U. – in the case of hemophilia, that’s the difference between treating 20,000 people in the U.S. and 400,000 worldwide. Our approach begins with a diverse portfolio of liver programs, and we are also creating delivery systems for other tissues including the eye, muscle and brain.
By solving for limitations in scope and scale with gene therapy, we’re determined to bring the profound benefits of this technology to patients around the world. If there’s anything we can take away from John Smith’s lament about penicillin in the 1940s, it’s that manufacturing can make the difference between a scientific breakthrough and a global revolution.
 American Chemical Society International Historic Chemical Landmarks (1999). Discovery and Development of Penicillin. (accessed September 3, 2019).